132 related articles for article (PubMed ID: 37812490)
21. Interferon-gamma production in response to in vitro stimulation with collagen type II in rheumatoid arthritis is associated with HLA-DRB1(*)0401 and HLA-DQ8.
Berg L; Rönnelid J; Sanjeevi CB; Lampa J; Klareskog L
Arthritis Res; 2000; 2(1):75-84. PubMed ID: 11219392
[TBL] [Abstract][Full Text] [Related]
22. Innate lymphoid cell disturbance with increase in ILC1 in systemic lupus erythematosus.
Guo C; Zhou M; Zhao S; Huang Y; Wang S; Fu R; Li M; Zhang T; Gaskin F; Yang N; Fu SM
Clin Immunol; 2019 May; 202():49-58. PubMed ID: 30926441
[TBL] [Abstract][Full Text] [Related]
23. Entecavir-induced interferon-λ1 suppresses type 2 innate lymphoid cells in patients with hepatitis B virus-related liver cirrhosis.
Wang SQ; Shen Y; Li J; Liu Y; Cheng LS; Wu SD; She WM; Jiang W
J Viral Hepat; 2021 May; 28(5):795-808. PubMed ID: 33482039
[TBL] [Abstract][Full Text] [Related]
24. IL23-Producing Human Lung Cancer Cells Promote Tumor Growth via Conversion of Innate Lymphoid Cell 1 (ILC1) into ILC3.
Koh J; Kim HY; Lee Y; Park IK; Kang CH; Kim YT; Kim JE; Choi M; Lee WW; Jeon YK; Chung DH
Clin Cancer Res; 2019 Jul; 25(13):4026-4037. PubMed ID: 30979738
[TBL] [Abstract][Full Text] [Related]
25. Checkpoint Inhibitors Modulate Plasticity of Innate Lymphoid Cells in Peripheral Blood of Patients With Hepatocellular Carcinoma.
Heinrich B; Ruf B; Subramanyam V; Myojin Y; Lai CW; Craig AJ; Fu J; Xie C; Kroemer A; Greten TF; Korangy F
Front Immunol; 2022; 13():849958. PubMed ID: 35833139
[TBL] [Abstract][Full Text] [Related]
26. Tofacitinib facilitates the expansion of myeloid-derived suppressor cells and ameliorates interstitial lung disease in SKG mice.
Sendo S; Saegusa J; Yamada H; Nishimura K; Morinobu A
Arthritis Res Ther; 2019 Aug; 21(1):184. PubMed ID: 31387650
[TBL] [Abstract][Full Text] [Related]
27. The Janus kinase inhibitor tofacitinib inhibits TNF-α-induced gliostatin expression in rheumatoid fibroblast-like synoviocytes.
Kawaguchi Y; Waguri-Nagaya Y; Tatematsu N; Oguri Y; Kobayashi M; Nozaki M; Asai K; Aoyama M; Otsuka T
Clin Exp Rheumatol; 2018; 36(4):559-567. PubMed ID: 29352846
[TBL] [Abstract][Full Text] [Related]
28. Intravenous immunoglobulin therapy enhances suppressive regulatory T cells and decreases innate lymphoid cells in children with immune thrombocytopenia.
Wang SC; Yang KD; Lin CY; Huang AY; Hsiao CC; Lin MT; Tsai YG
Pediatr Blood Cancer; 2020 Feb; 67(2):e28075. PubMed ID: 31736241
[TBL] [Abstract][Full Text] [Related]
29. Role of JAK-STAT signaling in the pathogenic behavior of fibroblast-like synoviocytes in rheumatoid arthritis: Effect of the novel JAK inhibitor peficitinib.
Emori T; Kasahara M; Sugahara S; Hashimoto M; Ito H; Narumiya S; Higashi Y; Fujii Y
Eur J Pharmacol; 2020 Sep; 882():173238. PubMed ID: 32561292
[TBL] [Abstract][Full Text] [Related]
30. The effects of suppressing inflammation by tofacitinib may simultaneously improve glycaemic parameters and inflammatory markers in rheumatoid arthritis patients with comorbid type 2 diabetes: a proof-of-concept, open, prospective, clinical study.
Di Muzio C; Di Cola I; Shariat Panahi A; Ursini F; Iagnocco A; Giacomelli R; Cipriani P; Ruscitti P
Arthritis Res Ther; 2024 Jan; 26(1):14. PubMed ID: 38178250
[TBL] [Abstract][Full Text] [Related]
31. Innate lymphoid cells in atherosclerosis.
Engelbertsen D; Lichtman AH
Eur J Pharmacol; 2017 Dec; 816():32-36. PubMed ID: 28449862
[TBL] [Abstract][Full Text] [Related]
32. Altered distribution and function of splenic innate lymphoid cells in adult chronic immune thrombocytopenia.
Audia S; Moulinet T; Ciudad-Bonté M; Samson M; Facy O; Ortega-Deballon P; Saas P; Bonnotte B
J Autoimmun; 2018 Sep; 93():139-144. PubMed ID: 30055825
[TBL] [Abstract][Full Text] [Related]
33. JAK inhibitor tofacitinib for treating rheumatoid arthritis: from basic to clinical.
Tanaka Y; Yamaoka K
Mod Rheumatol; 2013 May; 23(3):415-24. PubMed ID: 23212593
[TBL] [Abstract][Full Text] [Related]
34. Janus kinase inhibitors prevent migration of rheumatoid arthritis neutrophils towards interleukin-8, but do not inhibit priming of the respiratory burst or reactive oxygen species production.
Mitchell TS; Moots RJ; Wright HL
Clin Exp Immunol; 2017 Aug; 189(2):250-258. PubMed ID: 28369741
[TBL] [Abstract][Full Text] [Related]
35. Presence of innate lymphoid cells in allogeneic hematopoietic grafts correlates with reduced graft-versus-host disease.
Kroeze A; van Hoeven V; Verheij MW; Turksma AW; Weterings N; van Gassen S; Zeerleder SS; Blom B; Voermans C; Hazenberg MD
Cytotherapy; 2022 Mar; 24(3):302-310. PubMed ID: 35058143
[TBL] [Abstract][Full Text] [Related]
36. Tofacitinib modulates the VZV-specific CD4+ T cell immune response in vitro in lymphocytes of patients with rheumatoid arthritis.
Almanzar G; Kienle F; Schmalzing M; Maas A; Tony HP; Prelog M
Rheumatology (Oxford); 2019 Nov; 58(11):2051-2060. PubMed ID: 31106368
[TBL] [Abstract][Full Text] [Related]
37. The JAK inhibitor tofacitinib regulates synovitis through inhibition of interferon-γ and interleukin-17 production by human CD4+ T cells.
Maeshima K; Yamaoka K; Kubo S; Nakano K; Iwata S; Saito K; Ohishi M; Miyahara H; Tanaka S; Ishii K; Yoshimatsu H; Tanaka Y
Arthritis Rheum; 2012 Jun; 64(6):1790-8. PubMed ID: 22147632
[TBL] [Abstract][Full Text] [Related]
38. Identification of aceNKPs, a committed common progenitor population of the ILC1 and NK cell continuum.
Rodriguez-Rodriguez N; Clark PA; Gogoi M; Ferreira ACF; Kerscher B; Crisp A; Jolin HE; Murphy JE; Sivasubramaniam M; Pedro L; Walker JA; Heycock MWD; Shields JD; Barlow JL; McKenzie ANJ
Proc Natl Acad Sci U S A; 2022 Dec; 119(49):e2203454119. PubMed ID: 36442116
[TBL] [Abstract][Full Text] [Related]
39. Alteration of circulating innate lymphoid cells in patients with atherosclerotic cerebral infarction.
Li Q; Liu M; Fu R; Cao Q; Wang Y; Han S; Hu W; Li H; Hu C; Wu L; Zhang L; Deng J; Wang Y
Am J Transl Res; 2018; 10(12):4322-4330. PubMed ID: 30662674
[TBL] [Abstract][Full Text] [Related]
40. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
Traves PG; Murray B; Campigotto F; Galien R; Meng A; Di Paolo JA
Ann Rheum Dis; 2021 Jul; 80(7):865-875. PubMed ID: 33741556
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
